Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Melatonin and sleep hygiene feasibility trial for sleep disturbance in dementia
ACTRN12617000056392Phase 2Withdrawn
- Sponsor
- Flinders University
- Start
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of melatonin in Dementia (3 arms), sponsored by Flinders University. Primary endpoint: Activity and sleep patterns by activity monitor. Planned start Jan 2018; status: withdrawn.
02
Drugs
melatonin
03
Conditions
Dementia
Beyond the preview
Go deeper on ACTRN12617000056392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12617000056392.